#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4944	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2442	590.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1661	1661	C	680	C,T	615,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7830	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	549.8	0	.	n	.	0	T695C	SNP	695	695	T	1309	1309	C	580	C	526	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7830	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	549.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1951	1951	A	654	A,G	604,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7830	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	549.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2585	2585	C	697	C,G	623,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7830	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	549.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2659	2659	A	701	A,C	633,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7830	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	549.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3211	3211	C	681	C,T,A	594,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	666	folP	852	852	100.0	folP.l6.c4.ctg.1	2129	93.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1327	1329	AGC	141;142;141	A;G;C,G	130;130;128,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1626	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3977	122.4	1	SNP	p	S91F	0	.	.	271	273	TCC	888	890	TCC	109;109;108	T;C;C	98;99;102	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1626	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3977	122.4	1	SNP	p	D95N	0	.	.	283	285	GAC	900	902	GAC	111;111;111	G;A,T;C	102;102,1;101	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1626	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3977	122.4	1	SNP	p	D95G	0	.	.	283	285	GAC	900	902	GAC	111;111;111	G;A,T;C	102;102,1;101	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	750	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1829	122.8	0	.	p	.	0	A40P	NONSYN	118	120	GCC	752	754	CCC	155;156;157	C;C;C	145;148;145	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	750	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1829	122.8	1	SNP	p	G45D	0	.	.	133	135	GGC	767	769	GGC	154;155;154	G;G;C	145;145;144	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1532	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3588	128.0	1	SNP	p	D86N	0	.	.	256	258	GAC	871	873	GAC	165;165;165	G;A,C;C	151;141,1;150	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1532	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3588	128.0	1	SNP	p	S87I	0	.	.	259	261	AGT	874	876	AGT	163;163;163	A,C;G;T	148,1;153;149	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1532	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3588	128.0	1	SNP	p	S87R	0	.	.	259	261	AGT	874	876	AGT	163;163;163	A,C;G;T	148,1;153;149	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1532	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3588	128.0	1	SNP	p	S87W	0	.	.	259	261	AGT	874	876	AGT	163;163;163	A,C;G;T	148,1;153;149	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1532	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3588	128.0	1	SNP	p	S88P	0	.	.	262	264	TCC	877	879	TCC	162;163;160	T;C;C	151;150;152	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1268	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3349	113.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1859	1861	GGC	159;159;157	G,A;G;C,A	141,1;137;133,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1550	1552	GCA	176;175;175	G,T;C;A	162,1;165;168	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1553	1555	ATC	174;174;175	A;T;C,G	165;162;161,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1565	1567	GTG	177;176;177	G;T;G	162;162;161	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1565	1567	GTG	177;176;177	G;T;G	162;162;161	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2069	2071	ACC	146;147;147	A,C;C;C	127,1;133;137	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2123	2125	GCG	154;155;155	G;C,A;G,A	128;116,1;119,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2123	2125	GCG	154;155;155	G;C,A;G,A	128;116,1;119,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2246	2248	GGC	157;157;157	G,A;G;C	134,1;136;139	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2255	2257	GGC	158;157;157	G;G;C	140;139;139	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1266	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3036	124.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2273	2275	CCG	154;154;152	C,G;C;G	131,1;138;130	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1748	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3672	142.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	2027	2029	CTG	171;170;171	C;T;G	148;149;153	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	846	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2353	107.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	807	807	C	155	C	141	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	0	.	p	.	0	E41K	NONSYN	121	123	GAA	715	717	AAA	151;151;149	A;A;A	135;138;132	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	997	999	CTT	157;159;160	C;T;T	146;146;144	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1021	1023	GGA	157;155;152	G,A;G;A	147,1;141;141	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1105	1107	GGT	158;158;158	G;G;T	146;148;145	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1159	1161	AGC	162;161;161	A;G;C	147;142;146	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1225	1225	T	163	T	148	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	1	SNP	p	G120K	0	.	.	358	360	GGT	952	954	GGT	157;157;158	G;G;T	149;148;146	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	1	SNP	p	A121D	0	.	.	361	363	GCC	955	957	GCC	159;159;159	G;C;C	143;145;148	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	804	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1942	120.6	1	SNP	p	A121N	0	.	.	361	363	GCC	955	957	GCC	159;159;159	G;C;C	143;145;148	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3192	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5309	180.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2236	2238	AAT	188;187;185	A;A;TAAA,TAA	170;171;165,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	492	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1625	90.7	1	SNP	p	V57M	1	.	.	169	171	ATG	815	817	ATG	167;167;167	A;T;G	156;157;153	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
